TCTR20211015001招募中不适用
Rare and childhood cancer multi-omics for precision medicine
Health System Research Institute0 个研究点目标入组 1,000 人开始时间: 2021年10月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- N/A (No limit) 至 18 Years（—）
- 性别
- All
入选标准
- •Age less than 18 years with High-risk neuroblastoma, refractory or relapsed or Osteosarcoma or Non-rhabdosarcoma solid tumors or Brain tumors: embryonal tumors & diffused/high grade gliomas or Atypical teratoid/rhabdoid tumor
排除标准
- •1. No biological parents available
- •2. Refusal to participate in the study
研究者
相似试验
招募中
不适用
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesEndocrine TumorsRenal CancerSarcomaNeuroblastomaRetinoblastomaNCT01109394National Cancer Institute (NCI)6,035
招募中
2 期
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.Cancer2024-513779-42-02Oslo University Hospital HF100
已完成
不适用
An integrated multi-omics study of tumor heterogeneity in patients with treatment-resistant malignant cancermalignant cancerJPRN-UMIN000040181Kansai Electric Power Hospital100
招募中
不适用
Study on the Diagnostic Value of Multi-omics Combined Detection for Precancerous Lesions of CRCPrecancerous LesionInflammatory Bowel DiseasesColorectal CancerNCT05530746Changhai Hospital500
招募中
2 期
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelNeoplasmsNCT04449549National Cancer Institute (NCI)82